Bullish Case: Byron Allen's $4.7M purchase at $1.09 signals insider conviction, and mean-reverting price action has repeatedly defended the $1.00 area. Helium's density curve peaks near $1.00 (0.3668) versus the market's $0.50 tilt (0.3343), implying models see downside as overpriced. With historical return surface mass at small positive moves and short-squeeze history, any Q3 cash-runway clarity or ad/licensing catalyst could rapidly re-rate this $100M-cap name toward $1.40-$1.80.

Bearish Case: Puts traded 1,066% above call volume, and 10/16 put IVs (156%-500%) dwarf the November call skew — institutions are paying up for downside protection into a thinly traded ~$100M cap with 'substantial doubt' going-concern history. The Helium term structure shows extreme uncertainty spikes (344%-406% IV) at Oct/Nov nodes, and the SPY surface's elevated downside wings amplify gaps. Chronic losses plus dilution risk keep $0.50-$0.80 reachable.

Potential Outcomes:

• ~40% — BZFD drifts $0.85-$1.25 into December as Allen's support holds; falsified by closes below $0.75.
• ~25% — Bearish put-flow precedes a funding/dilution shock; price gaps to $0.50-$0.70; falsified if no 8-K/S-3 appears by mid-November.
• ~20% — Q3 earnings or cash-runway update triggers a squeeze toward $1.50-$2.00; falsified by no volume spike above ~2x average.
• ~15% — Momentum/liquidity breakdown drives a test of $0.50 or lower; falsified if bids hold above $0.80 on heavy tape.

Key signals: 8-K filings, 10-Q cash disclosure, December options OTC buildup.

September 30, 2026